Rapid Enrollment in ALTITUDE-AD Phase 2 Study
Completed enrollment of the 542-participant ALTITUDE-AD Phase 2 study in roughly 10 months, much faster than expected, attributed to the interest in Sabirnetug’s therapeutic potential and innovative participant screening methods.
Innovative Use of Plasma Biomarkers
Used plasma phospho-tau 217 screening to improve enrollment efficiency in ALTITUDE-AD, resulting in 81% of screened individuals testing positive on amyloid PET, compared to 40% in a previous study.
Presentations at Major Alzheimer's Conferences
Presented at ADPD and AAN conferences, highlighting innovative methods in Alzheimer’s drug development, including insights into synaptic biomarkers and A-beta oligomer selective assays.
Progress in Subcutaneous Administration
Completed a Phase 1 study comparing subcutaneous and intravenous administration of Sabirnetug, showing it was well-tolerated with systemic exposure supporting continued development.
Strong Financial Position
Held $197.9 million in cash and marketable securities, expected to support clinical and operational activities into early 2027.